Elixiron Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 32

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $31.6M

  • Investors
  • 17

Elixiron General Information

Description

Developer of immuno-therapeutics intended to aid patients designed for neurodegenerative diseases, Hepatitis B, and cancer. The company's drugs target specific immuno-suppressive pathways including graft-versus-host disease and macrophage activation syndrome, enabling patients to potentially harness the full power of the immune system to fight cancer.

Contact Information

Website
www.elixiron.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 16F-3, No. 508, Section 7, Zhongxiao East Road
  • Nangang District
  • Taipei
  • Taiwan
+886 02
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 16F-3, No. 508, Section 7, Zhongxiao East Road
  • Nangang District
  • Taipei
  • Taiwan
+886 02

Elixiron Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Elixiron Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 18-Jun-2025 $31.6M Completed Generating Revenue
7. Later Stage VC (Series A3) 01-Apr-2023 Completed Clinical Trials - General
6. Grant 01-Jul-2022 Completed Clinical Trials - General
5. Early Stage VC (Series A1) 16-Aug-2021 Completed Clinical Trials - General
4. Grant 01-Aug-2020 Completed Clinical Trials - General
3. Early Stage VC (Series A) 25-Jul-2019 Completed Clinical Trials - General
2. Seed Round 01-Apr-2018 $990K $2.82M Completed Startup
1. Seed Round 13-Jan-2017 $1.83M $1.83M Completed Startup
To view Elixiron’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Elixiron Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immuno-therapeutics intended to aid patients designed for neurodegenerative diseases, Hepatitis B, and canc
Drug Discovery
Taipei, Taiwan
32 As of 2026

Boston, MA
 

Beijing, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Elixiron Competitors (2)

One of Elixiron’s 2 competitors is Aprinoia Therapeutics, a Venture Capital-Backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aprinoia Therapeutics Venture Capital-Backed Boston, MA
NeoX Biotech Venture Capital-Backed Beijing, China
You’re viewing 2 of 2 competitors. Get the full list »

Elixiron Patents

  • 13

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Elixiron Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4746871-A2 Method of enhanced absorption of quinoxaline type iii receptor tyrosine kinase inhibitors Pending 18-Jul-2023
WO-2025019622-A2 Method of enhanced absorption of quinoxaline type iii receptor tyrosine kinase inhibitors Inactive 18-Jul-2023
WO-2025019622-A3 Method of enhanced absorption of quinoxaline type iii receptor tyrosine kinase inhibitors Inactive 18-Jul-2023
US-20240190934-A1 Engineered interleukin-10 and fusion proteins thereof Pending 28-Nov-2022
US-20250206837-A1 Anti-cd36 antibodies and uses thereof Active 07-Mar-2022 C07K16/2896
To view Elixiron’s complete patent history, request access »

Elixiron Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Elixiron Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Affinity Capital (Taiwan) Growth/Expansion Minority
Healthcare and Biopharmaceutical CVC Corporate Venture Capital Minority
Lotte Holdings Holding Company Minority
Maxpro Ventures Venture Capital Minority
Qisda Holding Company Minority
You’re viewing 5 of 17 investors. Get the full list »

Ready to get started?

Request a free trial

Elixiron FAQs

  • When was Elixiron founded?

    Elixiron was founded in 2017.

  • Where is Elixiron headquartered?

    Elixiron is headquartered in Taipei, Taiwan.

  • What is the size of Elixiron?

    Elixiron has 32 total employees.

  • What industry is Elixiron in?

    Elixiron’s primary industry is Drug Discovery.

  • Is Elixiron a private or public company?

    Elixiron is a Private company.

  • What is Elixiron’s current revenue?

    The current revenue for Elixiron is .

  • How much funding has Elixiron raised over time?

    Elixiron has raised $64.8M.

  • Who are Elixiron’s investors?

    Affinity Capital (Taiwan), Healthcare and Biopharmaceutical CVC, Lotte Holdings, Maxpro Ventures, and Qisda are 5 of 17 investors who have invested in Elixiron.

  • Who are Elixiron’s competitors?

    Aprinoia Therapeutics and NeoX Biotech are competitors of Elixiron.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process